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Abstract 
Rationale: The NMDA receptor antagonist, phencyclidine (PCP), has been shown to 
induce symptoms characteristic of schizophrenia.  A loss in executive function and the 
ability to shift attention between stimulus dimensions is impaired in schizophrenia; this 
can be assessed in rodents by the perceptual attentional set-shifting task.  Objective: The 
aim of this study was to investigate whether the deficits induced by sub-chronic PCP in 
attentional set-shifting could be reversed by sub-chronic administration of clozapine, 
risperidone or haloperidol.  Methods: Adult female hooded-Lister rats received sub-
chronic PCP (2 mg/kg) or vehicle (1 ml/kg) i.p. twice daily for seven days, followed by a 
seven-day washout period.  PCP-treated rats then received clozapine, risperidone, 
haloperidol or vehicle once daily for seven days and were then tested in the perceptual 
set-shifting task.  Results: PCP significantly (p<0.01) increased the number of trials to 
reach criterion in the EDS phase when compared to vehicle and this deficit was 
significantly (p<0.01) attenuated by sub-chronic clozapine (2.5 mg/kg) and risperidone 
(0.2 mg/kg), but not by sub-chronic haloperidol treatment (0.05 mg/kg).  Conclusions:  
These data show that sub-chronic PCP produced a robust deficit within the EDS phase in 
the attentional set-shifting task, in female rats.  Atypical antipsychotics, clozapine and 
risperidone, but not the classical agent, haloperidol, significantly improved the PCP-
induced cognitive deficit. 
 
Keywords Schizophrenia; Set-shifting; Phencyclidine; Rat; Atypical antipsychotics; 
Haloperidol 
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Introduction 
Impairments in executive function have long been considered a core feature of 
schizophrenia [17, 43, 54] as highlighted by the MATRICS initiative [44].  Novel 
antipsychotics are required to improve cognition as the CATIE study revealed that 
atypical antipsychotics, such as clozapine, show little efficacy against cognitive 
symptoms [38].  One aspect of executive function is the ability to modify behaviour in 
response to the changing relevance of a stimulus; this is frequently assessed in patients 
using the Wisconsin Card Sorting Test (WCST) [7] with impaired performance seen in 
patients with schizophrenia [27, 36, 47].  The perceptual attentional set-shifting task 
represents a rat analogue of the human WCST [8].  It investigates the ability to learn a 
rule and form an attentional set within the same sorting category (intra-dimensional shift 
(IDS), as well as the ability to shift attentional set between different sorting categories 
(extra-dimensional shift (EDS).  Analysis of the ID/ED task (from the CANTAB 
computerised test battery; [15]) in patients with schizophrenia has revealed significant 
impairments in the EDS phase [57]. 
The non-competitive NMDA receptor antagonist, phencyclidine (PCP), is a 
psychomotor stimulant drug that has been shown to induce symptoms characteristic of 
schizophrenia [30, 31].  PCP and its structural analogue ketamine produce inactivation of 
inhibitory control by decreasing GABA release [58].  This disinhibition of excitatory 
neurotransmission is referred to as NMDA receptor hypofunction [32, 45, 46].  Acute 
administration of PCP in rats has been shown to produce deficits in the novel object 
recognition-NOR-task [21], an operant reversal learning paradigm [1, 28] and attentional 
set-shifting [16].   
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Acute dosing with PCP has limitations in modelling the chronic psychotic illness 
or the persistent cognitive deficits of schizophrenic patients.  Alternatively, repeated sub-
chronic exposure to psychomotor stimulant drugs such as PCP, and d-amphetamine, 
produce enduring behavioural, molecular, structural and cellular changes, which are 
believed to mimic schizophrenia more accurately than acute dosing [18, 32, 56].  Post-
mortem analysis of brain tissue from schizophrenic patients has shown a reduction in 
GABAergic interneurons in the frontal cortex [5] and hippocampus [6].  We have 
recently demonstrated reduced density of parvalbumin immuno reactive neurons in the 
hippocampus and M1 (motor area 1) region of the frontal cortex following sub-chronic 
PCP treatment in the rat [3].  It has also been shown that chronic intermittent 
administration of PCP decreases parvalbumin mRNA expression in the prefrontal cortex 
of rats, and that this reduction can be reversed by clozapine but not haloperidol [11].  
These findings provide further support for the theory that sub-chronic PCP treatment in 
the rat provides a good correlate of the clinical condition.  Indeed, in our laboratory, 
administration of sub-chronic PCP to female rats (2 mg/kg twice daily for 7 days 
followed by 7 days drug free) produces deficits in reversal learning, attenuated by 
atypical but not classical antipsychotics [2].  Recently we have found that sub-chronic 
PCP-induced deficits in NOR are reversed by acute clozapine and risperidone, but not 
haloperidol [22].  Rodefer and colleagues combined the attentional set-shifting test with a 
sub-chronic dosage regimen (5 mg/kg twice daily for seven days followed by a ten-day 
drug washout period) and found a selective deficit in the EDS phase [49]. 
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The aim of this study was to investigate whether the deficits induced by our 
dosage regimen of sub-chronic PCP in attentional set-shifting could be reversed by sub-
chronic administration of clozapine, risperidone or haloperidol.   
 
Materials and methods 
 
Subjects 
Fifty female hooded-Lister rats (Harlan, UK), weighing 200-220 g at the start of the 
study, were used.  Animals were housed in groups of five, in a temperature-controlled 
room (21 ± 2 °C) at humidity of 45-55%, and maintained on a 12:12 h light/dark cycle 
(lights on at 0700h).  Experimental procedures were performed in the light phase.  All 
rats had free access to food (Special Diet Services, UK) and water until 1 week before 
testing began, at which point a minimal food restriction was imposed upon them (90% of 
free feeding bodyweight) but ad libitum access to water continued.  All experimental 
procedures were carried out in accordance with the Animals (Scientific Procedures) Act, 
UK (1986) and were approved by the University of Bradford ethical review process. 
 
Locomotor activity 
The locomotor activity (LMA) response to a novel environment was monitored using 
automated photocell cages.  The movement of each animal was monitored in a Plexiglas 
chamber (16 x 26 x 19 cm) covered with a compatible Plexiglas lid.  Counts were 
recorded by means of photo beam interruptions within the chamber.  Activity was 
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monitored every 5min over a 60-min period and summed to give a total count.  10 vehicle 
and 10 PCP-treated rats were tested in these chambers. 
 
Set-shifting apparatus 
The set-shifting apparatus was a modified version of that described originally by Birrell 
and Brown [8].  The test box was essentially a modified home cage measuring 59 x 35 x 
24 cm made of transparent plastic (Fig. 1).  A fixed 1 cm thick Plexiglas panel 
permanently divided 1/3 of the length of the box into two separate compartments (choice 
areas).  These two choice areas could be further isolated from each other with the aid of 
two removable Plexiglas panels that were lowered into place along wall mounted vertical 
sliders.  The digging bowls were placed in each choice area, and the rat was given access 
by lifting the divider(s) which could also be used to deny access to the bowls, such as 
when an incorrect choice was made.  A third removable panel divided the remaining 2/3 
length of the larger compartment into two sections when in place, along the horizontal 
(short) axis of the test box. 
 
Habituation and training 
Habituation to specific aspects of the testing paradigm commenced immediately 
following the end of the seven-day drug washout period.  Habituation to the testing box 
occurred for 1 hour on 3 consecutive days prior to training.  Two smooth ceramic circular 
digging pots (measuring 9cm in diameter by 5cm internal depth) identical to those 
intended for use during the testing phases were introduced to each home cage.  Each bowl 
was filled with grade 5 sawdust (also covering the home cage floor) and baited with food 
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reward in the form of several 1/4 honey nut loops (Kellogs, UK).   Digging bowls were 
continuously re-baited during this habituation period and remained in the home cage for 
the duration of the study.  Following habituation, all rats had to successfully complete the 
entire training regime in order to proceed to testing.  Rats were first trained to dig quickly 
and reliably in both bowls by progressively covering a single food reward per trial with 
incrementally thicker layers of digging media.  Once a rat had repeatedly demonstrated 
that it had acquired the training procedure, the dividing panels were introduced.  Digging 
itself was defined as a vigorous movement of front paws to displace digging media and 
obtain food reinforcement buried 2-2.5cm below surface level. 
The second phase of training introduced the concept of simple discrimination 
(SD) between first, medium and then, odour.  Rats were presented with identical digging 
bowls that had been anointed (smearing a few drops of oil around the rim of the bowl 
using a tissue) with two aromatic oils (Bodyshop, UK), only one of which was baited 
with food reward.  Placement of bowls in either the left or right compartment was 
randomised with the aid of an adapted pseudorandom Gellerman schedule.  Rats were 
permitted to explore both bowls for the first four trials irrespective of which bowl they 
dug in first, thereby acting as an opportunity to associate food reward with the positive 
predictor.  Subsequent incorrect selections ended a trial without the opportunity to 
explore the correct bowl.  A criterion for successful learning of each discrimination was 
set at 6 consecutive correct trials.  All exemplars used in training were not used during 
testing or at any other point in the study. 
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Testing paradigm 
In all cases rats were tested in the attentional set-shifting procedure 24 hours after 
training.  A trial was initiated by raising both dividers to give access to both digging 
bowls, only one of which was baited.  The first stage was the simple discrimination (SD), 
which was identical to the simple discrimination in the training session on the previous 
day, except new exemplars were used.  Testing continued until the rat reached a criterion 
of six consecutive correct responses.  In a test session, rats performed a series of 
discriminations (see Table 1).  For the compound discrimination (CD) a second 
dimension was introduced (odour), but the correct and incorrect exemplars remained the 
same (digging medium).  For the reversals the exemplars and relevant dimensions 
remained the same (medium) but the rats had to learn that the previously baited odour 
was now incorrect and the other odour was now the correct one.   New exemplars were 
used for the ID and ED shifts.  The specific exemplars used are shown in Table 2.  For 
the ED shift the previously irrelevant parameter (i.e. odour) was now relevant.  It has 
been shown that rats find the difficulty of each discrimination change, i.e. medium to 
odour or odour to medium, equivalent [8].  Therefore in simple discrimination digging 
medium was the relevant parameter for all rats. 
 
Drugs 
The study design involved five groups (n = 10 per group initially); rats were given either 
2 mg/kg PCP (n = 40) or vehicle (0.9% saline; n = 10) by the intraperitoneal (i.p.) route 
twice daily for seven days.  Dosing with sub-chronic PCP or vehicle was followed by a 
washout period of a further seven days.  Following the washout period, PCP-treated rats 
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were sub-chronically dosed for seven days (daily, i.p. route) with vehicle (0.9% saline), 
clozapine (2.5 mg/kg), haloperidol (0.05 mg/kg) or risperidone (0.2 mg/kg).  Rats were 
trained 30 minutes after dosing on the seventh day, and they were tested on day 8 30 
minutes after drug administration.     
The dose of haloperidol was chosen on the basis of a previous study showing that 
0.05 mg/kg haloperidol significantly attenuated a d-amphetamine-induced reversal 
learning impairment in female hooded-Lister rats [28].  Furthermore, this dose of 
haloperidol has been shown to occupy 50% of dopamine D2 receptors [34, 35].  The 
doses of clozapine and risperidone were chosen on the basis of our previous work 
showing efficacy against sub-chronic PCP in the reversal learning paradigm [2, 42] and 
NOR task [22].  PCP HCl (Sigma, UK) was dissolved in 0.9% saline.  Haloperidol 
(Serenace liquid, 2 mg/kg, Baker, UK) was diluted with distilled water.  Clozapine 
(Tocris, UK) and risperidone (provided by GSK, UK) were dissolved in a minimum 
volume of acetic acid, made up to volume with distilled water and pH adjusted to 6 with 
0.1M NaOH. 
Antipsychotics were given sub-chronically as a pilot study showed that acute 
dosing with clozapine and haloperidol prevented rats from being able to attend to the task 
due to slight sedation.  We used female rats in this experiment as a recent study in our 
laboratory showed that PCP produced a more robust effect in females in this task when 
compared to males [39] and more pronounced reductions in brain derived neurotrophic 
factor-BDNF [53].  This may be due to increased sensitivity of female rats to PCP, 
potentially caused by differences in pharmacokinetics [41, 51].  We have also shown that 
there is no effect of the oestrous cycle on cognitive performance in other tasks, also of 
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relevance to schizophrenia, such as NOR and that females perform better in the NOR task 
compared with males [55]. 
 
Data and statistical analysis 
LMA data were analysed by Student’s unpaired t-test and are expressed as total counts in 
a 60-min period.  Data for total trials to criterion (TTC) are expressed as mean ± SEM.  
Data were analysed by a two-way ANOVA (set-shifting phase x treatment group), 
followed by post-hoc analysis using Dunnett's t-test.  All analysis was performed using 
SPSS for Windows software (SPSS Inc., Version 13). 
 
Results 
 
Locomotor activity (LMA) 
Student’s unpaired t-test showed that PCP-treated rats were not significantly different in 
total LMA over the 60-min test period compared to vehicle-treated rats [p = 0.46;  Fig. 
2]. 
 
Attentional set-shifting performance 
A total of 42 rats were successfully trained and tested, rats were excluded from the study 
due to incompletion of the training within a single session as rats were required to 
complete the simple discriminations in training within 30 trials.  Extra trials were not 
given to ensure all rats had the same level of training before testing.  Treatment groups 
were vehicle + vehicle (n = 8), PCP + vehicle (n = 9), PCP + clozapine (n = 9), PCP + 
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haloperidol (n = 7) and PCP + risperidone (n = 9).  Drug treatment did not have any 
effect on performance during habituation or training (data not shown). 
A two-way ANOVA [drug treatment (vehicle, PCP, clozapine, haloperidol, 
risperidone)] x [set-shifting phase (SD, CD, Rev1, IDS, Rev2, EDS, Rev3)] showed a 
significant interaction [F4,37 = 5.4; p<0.01].  Total trials to criterion were observed to be 
lowest during the simple and compound discriminations and IDS phases with all rats 
requiring less than 7 trials [Fig. 3].  An increase in trials to criterion in reversal 1 was 
observed in all treatment groups, although these were not significant.  Haloperidol-treated 
rats required the most trials in reversal 1 to reach criterion [11.4 ± 1.4] compared to 
vehicle-treated rats [7.3 ± 0.6], however this increase was not significant [p = 0.08].  Rats 
required fewer trials to reach criterion in the IDS phase (6.0 ± 0) than the EDS phase (6.9 
± 0.6) and also completed the IDS trials more rapidly than the EDS trials (data not 
shown).  Post-hoc analysis within the EDS phase [Fig. 3] revealed that PCP significantly 
[p<0.01] increased the number of trials to reach criterion when compared to vehicle [from 
6.9 ± 0.6 to 15.7 ± 2.8].  This deficit was significantly [p<0.01] attenuated equally by 
sub-chronic clozapine [7.3 ± 0.6] and risperidone [7.3 ± 0.6], but not by sub-chronic 
haloperidol [14.3 ± 1.3]. 
 
Discussion 
The aim of the present study was to examine the effects of a sub-chronic PCP treatment 
regimen on attentional set-shifting ability in female rats and to investigate the effects of 
sub-chronic administration of antipsychotics.  The rodent version of this test was adapted 
by [8] from a previous version used in primates [48] and is a useful analogue of the 
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WCST [7].  This task requires rats to initially learn a rule, and then switch their attention 
to a new stimulus dimension, demonstrating cognitive flexibility.   
The present results show that in female rats, sub-chronic PCP produced a deficit 
in the ability to switch from one attentional set to another, indicated by a poor 
performance in the EDS stage of the task.  These deficits were reversed by sub-chronic 
administration of clozapine and risperidone, but not haloperidol.  There was no 
significant difference in locomotor activity observed between vehicle and sub-chronic 
PCP-treated groups; therefore it may be assumed that the cognitive deficit produced by 
sub-chronic PCP was independent of effects on locomotor activity.   
In this study rats readily learned to discriminate food bowls based on the digging 
medium and odour, and also refrained from digging in the un-baited bowls, therefore 
making few incorrect decisions.  In both vehicle and PCP-treated rats the first reversal 
(R1) required more trials to reach criterion compared to earlier stages of the task.  This is 
supported by data showing a significant increase in trials to criterion in control rats [26]; 
however, other studies have shown more modest increases [8, 16, 18]. 
Vehicle-treated rats required fewer trials to reach criterion in the IDS phase than 
the EDS phase and completed the IDS trials faster, suggesting that an attentional set was 
formed.  However, lack of a significant increase in trials to criterion from IDS to EDS 
does not support the idea that an attentional set had been formed in our control rats. One 
aspect of our study that may have influenced our data set is that, before each new 
discrimination begins, all rats have 4 discovery trials to learn the new rule; it is therefore 
possible that vehicle rats learned the EDS rule within these 4 trials thus improving their 
performance; this may also explain the occurrence of minimum trials to criterion without 
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any apparent errors in certain discriminations.  There was a significant increase in trials 
required to reach criterion in PCP-treated rats only in the EDS stage, suggesting that sub-
chronic PCP causes a selective deficit in attentional set-shifting ability.  These results are 
supported by a previous study where PCP at 5 mg/kg twice daily for seven days followed 
by a ten-day drug washout period, in male Long-Evans rats, selectively impaired the EDS 
without affecting other discrimination tasks or reversals [49].  Acute PCP (2.58 mg/kg) 
also produces a deficit in set-shifting ability in rats [16].  However, repeated exposure i.e. 
sub-chronic administration of PCP is believed to mimic schizophrenia more closely than 
acute administration [32].  The success of the treatment regime used in this investigation 
is further supported by a comparative study of sub-chronic PCP dosing regimes by 
Gartlon et al. [19] who reported that a bi-daily (7-day) regime, but not a 26-day 
intermittent regime, produces cognitive deficits in the NOR task.  Furthermore, recent 
studies have shown that long-term administration of PCP (3 mg/kg once per day 
administered Monday, Wednesday and Friday for 5 weeks, and 10 mg/kg daily for 14 
days) did not impair set-shifting ability in male rats [13, 18].  It is important to note that 
PCP is not the only pharmacological means of producing schizophrenia-like impairments, 
for example amphetamine sensitised rats show deficits in sensorimotor gating, in addition 
to cognitive impairment in tasks such as attentional set-shifting [18, 56]. 
It is clear that PCP given at various dosing schedules and in both sexes induces 
cognitive deficits.  However, there is evidence that the dosing schedule used here 
produces robust deficits in female rats as we have demonstrated long-term deficits in 
reversal learning [2, 3], NOR performance [22] and now attentional set-shifting in 
addition to neurobiological changes of relevance to schizophrenia such as reduced 
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parvalbumin and BDNF [3, 53].  These PCP-induced behavioural deficits in reversal 
learning and NOR are improved by atypical but not classical antipsychotics [2, 22, 42].  
Although beyond the scope of this manuscript, a full examination of sex and dosing 
schedule differences in the effects of PCP in different paradigms is required.  
Our study is not without limitations; e.g. the lack of a significant impairment in 
performance of vehicle treated animals from the IDS to the EDS phase. The use of 4 
discovery trials, as previously mentioned, before each new phase of the task may be an 
explanation for this.  The use of the discovery trials could explain this and also the 
apparent lack of errors as rats could learn the rule within these trials, and therefore not 
make any errors during the test.  A further limitation of the current experimental design 
was the decision not to counterbalance the dimension shifts, i.e. all the rats were switched 
from medium to odour.  Indeed, it would have improved our study if half the rats were 
switched from odour to medium at the EDS phase, although it has previously been shown 
that rats find the difficulty of each discrimination change, i.e. medium to odour or odour 
to medium, equivalent (Birrell and Brown, 2000).  The use of only one dose of 
antipsychotics is another limitation, a dose response should ideally have been conducted; 
however, in order to limit the number of animals used, and length of testing, we carefully 
selected one active dose of each antipsychotic.  The doses of clozapine and risperidone 
were chosen on the basis of our previous work showing efficacy against sub-chronic 
PCP-induced deficits in reversal learning [2, 42] and NOR [22].  The dose of haloperidol 
was chosen on the basis of our previous work showing that 0.05 mg/kg haloperidol 
significantly attenuated a d-amphetamine-induced reversal learning impairment in female 
hooded-Lister rats [28].  We believe a higher dose of haloperidol would not have been 
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any more effective as a dose of 0.075 mg/kg haloperidol was less efficacious to reverse 
the amphetamine deficit in reversal learning when compared to the dose of 0.05 mg/kg 
[28] and a dose of 0.1 mg/kg was shown to impair performance [1].  Furthermore 0.05 
mg/kg haloperidol has been shown to occupy 50% of dopamine D2 receptors [34, 35]. 
It has been widely reported that atypical antipsychotics have some beneficial 
effect on cognitive deficits [9, 23, 24, 40, 50].  However, it is important to appreciate the 
limitations of models such as this one as, although clozapine and risperidone effectively 
reversed the cognitive deficits observed in this experiment, the CATIE study highlights 
the fact that these antipsychotics do not provide consistent improvement of cognitive 
symptoms in patients [38].  Clearly, there is a need to develop more robust cognitive 
deficit models which are only partially improved by currently available antipsychotics, in 
order to correspond more closely with the clinical situation and allow for assessment of 
improved therapies. 
The current study shows that the PCP-induced deficit is improved by sub-chronic 
administration of clozapine and risperidone, but not haloperidol.  As mentioned above, 
these results are in agreement with previous studies in our laboratory.  In addition, we 
have recently shown that sub-chronic administration of clozapine (5 mg/kg) but not 
haloperidol (0.05 mg/kg) can prevent the PCP-induced cognitive deficit when 
administered in conjunction with the daily sub-chronic PCP treatment regimen [29].  
In this study, antipsychotics were given sub-chronically as a pilot study showed 
that acute dosing with clozapine and haloperidol prevented rats from being able to 
complete the task.  In order to make a direct comparison, risperidone was also given sub-
chronically.  Didriksen and colleagues used doses of 0.63 and 1.3 mg/kg of clozapine for 
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their reversal learning study as their pilot study showed worsening of performance with 
higher doses of clozapine in combination with PCP [14].  It has also been shown that 
tolerance can develop to the sedative effects of clozapine after repeated dosing [10].  Our 
data are supported by a study by Hashimoto and colleagues who showed that acute 
administration of clozapine (5 mg/kg) and haloperidol (0.1 mg/kg) did not improve a sub-
chronic PCP-induced cognitive deficit in the NOR task in mice; however, they found that 
sub-chronic administration of clozapine (5 mg/kg daily for 14 days) significantly 
improved the deficit, whereas sub-chronic haloperidol (0.1 mg/kg daily for 14 days) did 
not [25]. 
The current results show that sub-chronic administration of haloperidol did not 
significantly improve the deficit in set-shifting performance induced by PCP.  This is 
supported by clinical data as patients chronically treated with haloperidol have shown 
impaired performance in tests of working memory and executive function [20].  The 
inability of haloperidol to reverse the PCP-induced deficit may be due to its high D2 
receptor affinity and minimal 5-HT2A receptor affinity [52]. 
The current study does not provide direct evidence for specific receptor 
involvement in mediating the efficacy of the antipsychotics against the PCP effect, but 
data from receptor binding studies in other laboratories does allow us to suggest potential   
receptor mechanisms which may be involved.  Risperidone was highly effective in 
reversing the PCP-induced deficit and has high 5-HT2A and D2 receptor affinity [37].  
Risperidone is suggested to be the most effective atypical antipsychotic to improve 
working memory in the clinic [40], although, in this study in rats, clozapine was equally 
effective.  Clozapine has a lower affinity for D2 receptors than risperidone [4].  It is 
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believed that a 40-80% threshold of D2 receptor occupancy is required to achieve an 
antipsychotic response [35].  Clozapine is able to reach its antipsychotic response at 45-
65% D2 receptor occupancy levels [35].  Risperidone is only effective at occupancy 
levels above the threshold of 65%, suggesting that risperidone is more reliant upon its D2 
receptor affinity than clozapine.  Although risperidone and clozapine have high affinity 
for 5-HT2A receptors, it is unlikely that this mechanism alone is responsible for their 
antipsychotic action, as both have been shown to saturate 5-HT2 receptors at sub-
therapeutic doses [33].  Risperidone also has high affinity for D3, D4 and α2-
adrenoceptors, which may add to its therapeutic effect [52].  Clozapine has affinity at a 
wide range of receptors including 5-HT6 receptors.  A selective 5-HT6 receptor antagonist 
has been shown to improve set-shifting ability [26], this may be via facilitation of cortical 
and hippocampal glutamatergic activity [12]. 
In conclusion, sub-chronic PCP administration impairs attentional set-shifting 
ability in female rats as demonstrated by poor performance in the EDS stage of the task.  
This and previous data suggest that NMDA antagonists provide a reliable means of 
inducing impairments in set-shifting ability as well as other cognitive deficits of 
relevance to schizophrenia.  To our knowledge this is the first study to demonstrate that 
sub-chronic treatment with the atypical antipsychotics, clozapine and risperidone, is 
effective in reversing the PCP-induced cognitive deficit in the attentional set-shifting 
task, and that, the typical antipsychotic, haloperidol, is ineffective.  These data strengthen 
the predictive validity of the rat attentional set-shifting model. 
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Tables 
Table 1  Order of discriminations 
Discriminations
Relevant Irrelevant Rewarded Unrewarded
SD Medium Odour M1 M2
CD Medium Odour M1/O1 M2/O1
M1/O2 M2/O2
Rev1 Medium Odour M2/O1 M1/O1
M2/O2 M1/O2
IDS Medium Odour M3/O3 M4/O3
M3/O4 M4/O4
Rev2 Medium Odour M4/O3 M3/O3
M4/O4 M3/O4
EDS Odour Medium O5/M5 O6/M5
O5/M6 O6/M6
Rev3 Odour Medium O6/M5 O5/M5
O6/M6 O5/M6
Dimensions Exemplar combinations
 
 
 
Table 2  Specific exemplars used (presented in pairs) 
 
Dimension Pairing 1 (CD) Pairing 2 (IDS) Pairing 3 (EDS) 
Odour Rose = O1 
White flower = O2 
Green Meadow = O3 
Coconut = O4 
Orange = O5 
Almond = O6 
Medium 
 
Wood shavings = M1 
Cat litter = M2 
Small pebbles = M3 
Aspen = M4 
Fine sawdust = M5 
Wood blocks = M6 
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Legends 
 
Table 1 Overall order of discriminations presented to rats undertaking the attentional set-
shifting task.  Only rewarded stimuli were baited with food reward.  [M1 = medium 1; 
O1 = odour 1].  Table adapted from Birrell and Brown (2000).   
 
Table 2 Specific exemplars used in each phase of attentional set-shifting.  Odours were 
applied around the rims of digging bowls which were filled with various digging media 
depending upon the phase being tested.  The significance of pairing within a test phase 
ensures that for example rose is always accompanied with white flower within a test trial 
[O = Odour, M = Medium]. 
 
Fig. 1 Plan view of attentional set-shifting test box, showing gross dimensions, division 
into thirds and then into sixths to create two choice areas.  Dotted lines indicate 
removable Plexiglas dividers and unbroken lines indicate fixed panels and walls.   
 
Fig. 2 The effect of sub-chronic PCP (2 mg/kg) on locomotor activity in a novel 
environment.  Data are expressed as mean ± SEM activity counts over a 60-min period (n 
= 10 per group).  No significant difference between the groups.  
 
Fig. 3 The effect of sub-chronic PCP (2 mg/kg; n = 9) against vehicle-treated (n = 8) 
female rats on trials to reach criterion in attentional set-shifting and effects of sub-chronic 
administration of clozapine (2.5 mg/kg; n = 9), haloperidol (0.05 mg/kg; n = 7), 
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risperidone (0.2 mg/kg; n = 9) in PCP-treated rats.  Data are expressed as mean ± SEM 
and were analysed by two-way ANOVA and post-hoc Dunnett’s t-test (p < 0.01# 
compared to vehicle group in EDS; p < 0.01* compared to PCP group in EDS).  Simple 
discrimination (SD), compound discrimination (CD), reversal 1 (Rev1), intra-
dimensional shift (IDS), reversal 2 (Rev2), extra-dimensional shift (EDS), reversal 3 
(Rev3). 
